Krsnaa Diagnostics has received board approval for the issuance of Non-Convertible Debentures (NCDs) worth ₹430.00 crores, following its earlier regulatory approval. The board meeting held on December 12, 2025, which commenced at 11:30 AM and concluded at 12:40 PM, formally approved the issuance of unlisted, secured, redeemable and transferable NCDs on a private placement basis.

Board Meeting and Approval Details

The company's board of directors has provided comprehensive approval for the NCD structure and terms. The following table outlines the key decisions made during the board meeting:

NCD Structure and Terms

The approved NCDs will have a structured repayment mechanism with specific tenure and interest payment schedules. The debentures are designed as unlisted, secured instruments with comprehensive terms for investor protection.

Security and Redemption Framework

The NCDs will be secured through charges created over identified assets of the company as per definitive agreements. The redemption structure provides for systematic repayment commencing six months from the allotment date, with both interest and principal payable on a half-yearly basis through thirteen equal instalments.

The debentures will carry all rights and privileges as provided under the Companies Act, 2013, and terms specified in the definitive agreements. This structured approach ensures investor protection while providing the company with medium-term funding solutions.

Strategic Capital Access

This board approval follows the earlier regulatory clearance, enabling Krsnaa Diagnostics to access debt capital markets through the private placement route. The NCD issuance provides the healthcare diagnostics company with an alternative financing mechanism beyond traditional banking channels, supporting its operational requirements and growth initiatives in the competitive healthcare sector.

Krsnaa Diagnostics , one of India's largest integrated diagnostic service providers, has reported a robust financial performance for the second quarter of fiscal year 2026, showcasing significant growth across key metrics.

Financial Highlights

The company achieved an all-time high quarterly profit after tax (PAT) of INR 239.00 million, marking a substantial 22% year-over-year increase from INR 196.00 million in Q2 FY25. This growth was primarily driven by strengthening margins and improved operating leverage.

Here's a breakdown of Krsnaa Diagnostics' Q2 FY26 financial performance:

Operational Performance

Krsnaa Diagnostics continued to expand its reach and enhance its service offerings:

• Served 5.4 million patients in Q2 FY26, a 4% increase from the previous year
• Performed 16.4 million tests, slightly down by 4% compared to Q2 FY25
• Increased NABL-accredited pathology labs to 57, up 54% from 37 in Q2 FY25
• Expanded NABH-accredited radiology centers to 36, a 50% growth from 24 in the previous year

Retail Business Growth

The company's retail segment showed remarkable progress:

• Retail revenue surged to INR 174.00 million in Q2 FY26, up from INR 16.00 million in Q2 FY25
• Retail revenue contribution to group revenue increased from 1% to 8% year-over-year
• Number of retail touch points grew significantly from 5 to 2,878

Expanding Footprint

Krsnaa Diagnostics has strengthened its presence across India:

• Operates in 18 states and union territories
• Runs 186 CT/MRI centers and 120 pathology labs
• Manages over 3,500 patient collection centers

Future Outlook

The company's existing order book is set to expand its network to over 200 CT/MRI centers, potentially making it one of Asia's largest radiology players. Additionally, the Rajasthan project is expected to significantly boost Krsnaa's pathology network, enhancing its accessibility across India.

Commitment to Affordable Healthcare

Krsnaa Diagnostics continues to offer diagnostic services at rates approximately 70% below market prices across radiology, pathology, and tele-radiology services through its public-private partnership model. This approach has enabled the company to serve over 75 million patients since its inception, making quality healthcare more accessible to a broader population.

As Krsnaa Diagnostics maintains its growth trajectory, it demonstrates that providing affordable diagnostic services can go hand-in-hand with strong financial performance and market expansion.